Congress highlights – ASCO 2016 special edition: Highlights in genitourinary cancers

From June 3rd till June 8th, Chicago was host for the 52nd ASCO annual meeting. The theme for this year’svenue was ‘Collective Wisdom: The Future of Patient-Centred Care and Research’. With almost 35,000registered attendees from over 100 countries worldwide and about 6,000 submitted abstracts, thisyear’s meeting was a great success. This report will highlight 10 key studies concerning genitourinarycancers presented during the meeting.From June 3rd till June 8th, Chicago was host for the 52nd ASCO annual meeting. The theme for this year’svenue was ‘Collective Wisdom: The Future of Patient-Centred Care and Research’. With almost 35,000registered attendees from over 100 countries worldwide and about 6,000 submitted abstracts, thisyear’s meeting was a great success. This report will highlight 10 key studies concerning genitourinarycancers presented during the meeting.

Highlights in genitourinary cancers

From June 1st till June 5th, Chicago was host for the 55th annual ASCO meeting. This report will highlight the most important studies concerning genitourinary cancers presented during the meeting

Congress highlights – ESMO 2016 special edition: Highlights in genitourinary cancers

From the 8th till the 12th of September, Madrid was the host city for the 2017 ESMO Congress. The central theme of the congress was ‘Integrating science into oncology for a better patient outcome’, as it is crucial that researchers and clinicians exchange knowledge in an era of deep understanding of the molecular biology underlying the development of cancer. ESMO 2017 was attended by almost 24,000 registered attendees. This report will highlight eleven key studies concerning genitourinary cancers presented during the meetin

Congress highlights : ESMO 2018 special edition : highlights in genitourinary cancers

From the 19th till the 23rd of September, Munich was host for the 2018 ESMO Congress. The central theme of the congress was ‘Securing access to optimal cancer care’. This year’s venue was attended by more than 25,000 registered attendees. This report will highlight 10 key studies concerning genitourinary cancers presented during the meeting

Necrotizing myopathy as a paraneoplastic syndrome associated with renal cell carcinoma

We report a 49-year-old patient with necrotizing myopathy and a right renal mass. After laparoscopic radical nephrectomy, a remission of myopathy was seen. Pathologic evaluation of the nephrectomy specimen revealed a clear cell renal cell carcinoma. Relapse of myopathy 6 months postoperatively coincided with the diagnosis of the appearance of liver metastatic disease. After initiation of treatment with an mTOR-inhibitor, myopathy became less active requiring smaller amounts of corticosteroids with a complete remission of myopathy after 3 months of systemic treatment for metastatic renal cell cancer

Diagnostic accuracy of urinary prostate protein glycosylation profiling in prostatitis diagnosis

Introduction: Although prostatitis is a common male urinary tract infection, clinical diagnosis of prostatitis is difficult. The developmental mechanism of prostatitis is not yet unraveled which led to the elaboration of various biomarkers. As changes in asparagine-linked-(N-)-glycosylation were observed between healthy volunteers (HV), patients with benign prostate hyperplasia and prostate cancer patients, a difference could exist in biochemical parameters and urinary N-glycosylation between HV and prostatitis patients. We therefore investigated if prostatic protein glycosylation could improve the diagnosis of prostatitis. Materials and methods: Differences in serum and urine biochemical markers and in total urine N-glycosylation profile of prostatic proteins were determined between HV (N = 66) and prostatitis patients (N = 36). Additionally, diagnostic accuracy of significant biochemical markers and changes in N-glycosylation was assessed. Results: Urinary white blood cell (WBC) count enabled discrimination of HV from prostatitis patients (P < 0.001). Urinary bacteria count allowed for discriminating prostatitis patients from HV (P < 0.001). Total amount of biantennary structures (urinary 2A/MA marker) was significantly lower in prostatitis patients compared to HV (P < 0.001). Combining the urinary 2A/MA marker and urinary WBC count resulted in an AUC of 0.79, 95% confidence interval (CI) = (0.70-0.89) which was significantly better than urinary WBC count (AUC = 0.70, 95% CI = [0.59-0.82], P = 0.042) as isolated test. Conclusions: We have demonstrated the diagnostic value of urinary N-glycosylation profiling, which shows great potential as biomarker for prostatitis. Further research is required to unravel the developmental course of prostatic inflammation